Transdermal Science · Research briefing

Hydrophilic + Lipophilic Co-Loading: How Dual-Solubility Nanocarriers Deliver Multi-Active Formulations in One Step

Most multi-active routines exist because one vehicle cannot hold both water-loving and oil-loving molecules. Dual-solubility nanocarriers change that, which matters for both regimen design and transdermal science.

Answer first

Dual-solubility nanocarriers hold water-soluble actives in polar or aqueous domains and oil-soluble actives in lipid lamellae within the same particle. One vehicle can then deliver molecules such as niacinamide and a retinoid together, at controlled ratios, without separate serums and creams. Cetosomes® do this through a polar mantle around a cetylated lamellar core.

The solubility split behind most routines

Skin actives fall into two broad camps. Hydrophilic molecules such as niacinamide, tranexamic acid, ascorbic acid, urea and the AHAs dissolve in water and partition poorly into the lipid-rich stratum corneum. Lipophilic molecules such as retinoids, ceramides, tocopherol and many botanicals dissolve in oils and can be poorly bioavailable from water-based serums. Every topical drug also faces the size threshold: penetration falls steeply above about 500 Da.[2]

That is why most multi-step routines exist. A water serum carries the hydrophilic active, a cream carries the lipophilic one, and the patient is left to work out the order, the wait times and the interactions. Each extra product adds solvents, preservatives and surfactants to the barrier.

How co-loading works

A dual-solubility nanocarrier has internal domains of different polarity, which lets a single particle hold both kinds of molecule.

Carrier

Hydrophilic site

Lipophilic site

Notes

Liposome

Aqueous core

Phospholipid bilayer

Bilayer capacity limited; storage instability[3]

Ethosome

Aqueous/ethanolic core

Bilayer

Relies on high ethanol content[6]

Transfersome

Aqueous core

Deformable bilayer

Edge activator required[5]

Cetosome®

Polar solvent and surfactant mantle

Cetylated lamellae; oil-cored particles

Two particle populations; ζ −22 to −55 mV[1]

The patent describes cetosome assembly in phases. Hydrocarbon chains align into the core while polar solvent and solubiliser molecules form an outer corona, or mantle. These polar components "may be incorporated to some degree within the core matrix, which allow for the entry and additional capture of both polar and other hydrophobic bioactive molecules."[1] When oil or a non-polar ingredient is added, cetosomes form around it, giving a second, larger particle population that holds more lipophilic cargo.

Tuning the carrier to the active

Cetosomes can be tuned by choosing components that suit a particular permeant: functional groups with polar affinity for more ionic drugs such as diclofenac, or more lipophilic ones for non-polar permeants. The composition and molar ratios then set the release behaviour.[1] Co-loading is therefore a design choice made for each pair of actives, not a generic property.

Why one step matters clinically

  • Fixed ratios. The niacinamide-to-retinoid ratio is set by the formulator, not by how much of each product a patient uses.
  • Fewer vehicles on the barrier. One base replaces two or three, reducing total exposure to solvents and surfactants.
  • Synchronised release. Both actives come from the same reservoir on the same timescale.
  • Better adherence. Every step removed from a routine removes a chance to skip it.

Beyond skincare: transdermal co-delivery

Transdermal drug delivery has advanced through successive approaches: small lipophilic drugs in patches first, then chemical enhancers, then physical methods and carrier systems.[4] Dual-solubility carriers extend this by allowing a drug to be paired with an adjuvant, or two drugs with different polarities, in one dosage form. The cetosome patent family describes formulation feasibility across analgesics, anti-inflammatories and anticholinergics, including clinical and pharmacokinetic examples.[1]

Limitations

Co-loading is a matter of compatibility. Two actives in one particle can still interact chemically (for example, pH-dependent stability conflicts), and loading capacity is finite. Each pairing needs its own assay, stability and release testing. Co-loading combines delivery; it does not remove the need for evidence that each active works.

Frequently asked

Can one product deliver both water-soluble and oil-soluble actives?

Yes. With a dual-solubility nanocarrier, hydrophilic molecules sit in the carrier's polar or aqueous domains and lipophilic molecules sit in its lipid layers, so both are delivered from a single vehicle at a fixed ratio.

Why is co-loading better than layering serums?

Layering depends on application order, wait times and how products interact on the skin, and it multiplies the vehicle components the barrier is exposed to. Co-loading fixes the ratio, simplifies the routine and puts both actives into one controlled-release system.

Which nanocarriers can co-load hydrophilic and lipophilic actives?

Liposomes, niosomes, ethosomes and transfersomes can carry both in principle, in the aqueous core and the bilayer. Cetosomes® use a polar solvent and surfactant mantle around a cetylated lamellar core, and can also form larger particles around an oil phase for higher lipophilic loading.


References

  1. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  2. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  3. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics 332(1–2):1–16. 2007.DOI 10.1016/j.ijpharm.2006.12.005
  4. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology 26(11):1261–1268. 2008.DOI 10.1038/nbt.1504
  5. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochimica et Biophysica Acta — Biomembranes 1104(1):226–232. 1992.DOI 10.1016/0005-2736(92)90154-E
  6. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release 65(3):403–418. 2000.DOI 10.1016/S0168-3659(99)00222-9

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.